Source: Healio News
Clinicians who treat patients with chimeric antigen receptor T cells have become adept at identifying and treating acute neurotoxicity, a common adverse event associated with the therapy.
Researchers from Mount Sinai published a case study in Nature Medicine about a patient who developed neurocognitive and hypokinetic movement disorder with features of Parkinson’s disease after receiving ciltacabtagene autoleucel (Janssen, Legend Biotech). The patient received the therapy — a B-cell maturation antigen (BCMA)-targeted CAR-T in development as a treatment for advanced multiple myeloma —